All articles tagged with #preclinical trials
Researchers at the University of Waterloo are developing engineered Clostridium sporogenes that can colonize the oxygen-poor core of solid tumors and survive near the tumor’s outer layers by a quorum-sensing–controlled oxygen-tolerance gene, enabling tumor consumption from inside with GFP-based validation and plans for preclinical tumor testing.
Researchers at the University of Waterloo engineered the soil bacterium Clostridium sporogenes to colonize oxygen-poor solid tumors and consume nutrients, effectively attacking tumors from within. They added oxygen-tolerance tweaks and quorum-sensing controls, plus a fluorescent signal, to signal successful tumor disruption. While promising, the approach is still in preclinical stages with the goal of combining traits into a single bacterium for upcoming preclinical testing in humans.